References

1

Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007; 109: 1870–7. doi:10.1182/blood-2006-06-029850.

2

Knoebl P, Marco P, Baudo F, Collins P, Huth-Kühne A, Nemes L, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10: 622–31. doi:10.1111/j.1538-7836.2012.04654.x.

3

Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21–35. doi:10.1046/j.1365-2141.2003.04162.x.

4

Borg J, Guillet B, Le Cam-Duchez V, Goudemand J, Lévesque H, Group SS. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l’Hémophilie Acquise) registry. Haemophilia 2013; 19: 564–70. doi:10.1111/hae.12138.

5

Huang S-Y, Tsay W, Lin S-Y, Hsu S-C, Hung M-H, Shen M-C. A study of 65 patients with acquired hemophilia A in Taiwan. J Formos Med Assoc 2015; 114: 321–7. doi:10.1016/j.jfma.2013.01.006.

6

Tiede A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kühne A, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015; 125: 1091–7. doi:10.1182/blood-2014-07-587089.

7

Franchini M, Capra F, Nicolini N, Veneri D, Manzato F, Baudo F, et al. Drug-induced anti-factor VIII antibodies: a systematic review. Med Sci Monit 2007; 13: RA55–61.

8

Pavlova A, Diaz-Lacava A, Zeitler H, Satoguina J, Niemann B, Krause M, et al. Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls. Haemophilia 2008; 14: 355–60. doi:10.1111/j.1365-2516.2007.01618.x.

9

Oldenburg J, Fosså SD, Ikdahl T. Genetic variants associated with cisplatin-induced ototoxicity. Pharmacogenomics 2008; 9: 1521–30. doi:10.2217/14622416.9.10.1521.

10

Tiede A, Eisert R, Czwalinna A, Miesbach W, Scharrer I, Ganser A. Acquired haemophilia caused by non-haemophilic factor VIII gene variants. Ann Hematol 2010; 89: 607–12. doi:10.1007/s00277-009-0887-3.

11

Hay CR, Brown S, Collins PW, Keeling D, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591–605. doi:10.1111/j.1365-2141.2006.06087.x.

12

Verbruggen B, Novakova I, Wessels H, Boezeman J, Berg M van den, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 74: 247–51. doi:10.1055/s-0038-1653759.

13

Baudo F, Collins P, Huth-Kuehne A, Levesque H, Marco P, Nemes L, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120: 39–46. doi:10.1182/blood-2012-02-408930.

14

Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546–51. doi:10.1182/blood-2006-04-017988.

15

Schneiderman J, Rubin E, Nugent D, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244–8. doi:10.1111/j.1365-2516.2007.01451.x.

16

Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10: 169–73. doi:10.1046/j.1365-2516.2003.00856.x.

17

Borg J-Y, Négrier C, Durieu I, Dolimier E, Masquelier A-M, Lévesque H, et al. FEIBA in the treatment of acquired haemophilia a: results from the prospective multicentre French ‘FEIBA dans l’hemophilie A acquise’(FEIBHAC) registry. Haemophilia 2015; 21: 330–7. doi:10.1111/hae.12574.

18

Sumner M, Geldziler B, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 2007; 13: 451–61. doi:10.1111/j.1365-2516.2007.01474.x.

19

Varadi K, Negrier C, Berntorp E, Astermark J, Bordet J-C, Morfini M, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374–80. doi:10.1046/j.1538-7836.2003.00450.x.

20

Holmström M, Tran H, Holme P. Combined treatment with APCC (FEIBA) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A–a two-centre experience. Haemophilia 2012; 18: 544–9. doi:10.1111/j.1365-2516.2012.02748.x.

21

Zanon E, Pasca S, Siragusa S, Napolitano M, Santoro C, Mameli L, et al. Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry. Thromb Res 2019; 174: 24–6. doi:10.1016/j.thromres.2018.12.006.

22

Qi X, Zhao Y, Li K, Fan L, Hua B. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors. Blood Coagul Fibrinolysis 2014; 25: 754–60. doi:10.1097/MBC.0000000000000137.

23

Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112: 250–5. doi:10.1182/blood-2008-03-143586.

24

Tiede A, Collins P, Knoebl P, Teitel J, Kessler C, Shima M, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 2020. doi:10.3324/haematol.2019.230771.

25

Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566–75. doi:10.3324/haematol.2008.001743.

26

Kruse-Jarres R, St-Louis J, Greist A, Shapiro A, Smith H, Chowdary P, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015; 21: 162–70. doi:10.1111/hae.12627.

27

Fosbury E, Drebes A, Riddell A, Chowdary P. Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A. Ther Adv Hematol 2017; 8: 263–72. doi:10.1177/2040620717720861.

28

Möhnle P, Pekrul I, Spannagl M, Sturm A, Singh D, Dechant C. Emicizumab in the treatment of acquired haemophilia: a case report. Transfus Med Hemother 2019; 46: 121–3. doi:10.1159/000497287.

29

Knoebl P, Thaler J, Jilma P, Quehenberger P, Gleixner KV, Sperr WR. Emicizumab for the treatment of acquired hemophilia A. Blood 2020. doi:10.1182/blood.2020006315.

30

Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200–3.

31

Franchini M, Castaman G, Coppola A, Santoro C, Zanon E, Di Minno G, et al. Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus 2015; 13: 498. doi:10.2450/2015.0141-15.

32

Collins GP, Parker AN, Pocock C, Kayani I, Sureda A, Illidge T, et al. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. Br J Haematol 2014; 164: 39. doi:10.1111/bjh.12582.

33

Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol 2017; 92: 695–705. doi:10.1002/ajh.24777.

34

Hay C. The 2000 United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) inhibitor guidelines. Pathophysiol Haemost Thromb 2002; 32: 19–21. doi:10.1159/000057295.

35

Collins P, Baudo F, Knoebl P, Lévesque H, Nemes L, Pellegrini F, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120: 47–55. doi:10.1182/blood-2012-02-409185.

37

Lian EC, Larcada AF, Chiu AY. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110: 774–8. doi:10.7326/0003-4819-110-10-774.

37

Lian EC, Larcada AF, Chiu AY. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110: 774–8. doi:10.7326/0003-4819-110-10-774.

38

Pardos-Gea J, Altisent C, Parra R, Vilardell-Tarres M, Ordi-Ros J. Acquired haemophilia A. First line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up study. Haemophilia 2012; 18: 789–93. doi:10.1111/j.1365-2516.2012.02772.x.

39

Nemes L. The use of immune tolerance induction regimens for acquired hemophilia. Haemophilia 2004; 10: 54.

40

Lian EC-Y, Villar MJ, Noy LI, Ruiz-Dayao Z. Aquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone. Am J Hematol 2002; 69: 294–5. doi:10.1002/ajh.10070.

41

Zeitler H, Ulrich-Merzenich G, Hess L, Konsek E, Unkrig C, Walger P, et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 2005; 105: 2287–93. doi:10.1182/blood-2004-05-1811.

42

Goldmann G, Marquardt N, Horneff S, Oldenburg J, Zeitler H. Treatment of minor severe acquired haemophilia. Is there a rationale for immunoadsorption? Atheroscler Suppl 2015; 18: 74–9. doi:10.1016/j.atherosclerosissup.2015.02.015.